Patents by Inventor Jane S. Lebkowski
Jane S. Lebkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030211603Abstract: Described in this disclosure is a new process whereby cells of one tissue type can be reprogrammed to produce cells of a different tissue type. Cells from a human donor are reprogrammed by culturing adjacent to primate pluripotent stem cells (in an undifferentiated or newly differentiated state) or in an environment supplemented by components taken from pPS cells. Simultaneously or in a subsequent step, the donor cells can be treated in a manner that enhances differentiation towards a different tissue type. In this manner, patients in need of tissue regeneration can be treated with cells differentiated and reprogrammed from their own autologous cell donation.Type: ApplicationFiled: February 12, 2003Publication date: November 13, 2003Inventors: David J. Earp, Melissa K. Carpenter, Joseph D. Gold, Jane S. Lebkowski, J. Michael Schiff
-
Patent number: 6576464Abstract: This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in depletion of undifferentiated cells, or expression of a marker that can be used to remove them later. Suitable effector sequences encode a toxin, a protein that induces apoptosis, a cell-surface antigen, or an enzyme (such as thymidine kinase) that converts a prodrug into a substance that is lethal to the cell. The differentiated cell populations produced according to this disclosure are suitable for use in tissue regeneration, and non-therapeutic applications such as drug screening.Type: GrantFiled: February 13, 2001Date of Patent: June 10, 2003Assignee: Geron CorporationInventors: Joseph D. Gold, Jane S. Lebkowski
-
Publication number: 20030095989Abstract: Described in this disclosure is a system for gene therapy using a chimeric vector made from an adenovirus genome and a heterologous gene that functionally replaces an adenovirus gene required for replication or assembly. Cytolytic viruses can be produced that target particular tissue types by virtue of having replication controlled by a specific transcription control element—such as the promoter for telomerase reverse transcriptase. These therapeutic viruses are believed to have an improved safety and efficacy profile compared with previously available systems.Type: ApplicationFiled: December 17, 2001Publication date: May 22, 2003Inventors: John M. Irving, Jane S. Lebkowski
-
Publication number: 20030040111Abstract: This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in depletion of undifferentiated cells, or expression of a marker that can be used to remove them later. Suitable effector sequences encode a toxin, a protein that induces apoptosis, a cell-surface antigen, or an enzyme (such as thymidine kinase) that converts a prodrug into a substance that is lethal to the cell. The differentiated cell populations produced according to this disclosure are suitable for use in tissue regeneration, and non-therapeutic applications such as drug screening.Type: ApplicationFiled: May 7, 2002Publication date: February 27, 2003Inventors: Joseph D. Gold, Jane S. Lebkowski
-
Publication number: 20020098582Abstract: This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in depletion of undifferentiated cells, or expression of a marker that can be used to remove them later. Suitable effector sequences encode a toxin, a protein that induces apoptosis, a cell-surface antigen, or an enzyme (such as thymidine kinase) that converts a prodrug into a substance that is lethal to the cell. The differentiated cell populations produced according to this disclosure are suitable for use in tissue regeneration, and non-therapeutic applications such as drug screening.Type: ApplicationFiled: February 13, 2001Publication date: July 25, 2002Inventors: Joseph D. Gold, Jane S. Lebkowski
-
Patent number: 5807686Abstract: A cell population which is composed of cells bearing the stem cell marker CD34 and which are small in size and have little granulation are obtained by separating low density mononuclear hematopoietic cells according to size and then selecting for CD34.sup.+ cells in the smallest size fraction. The size of the cell population corresponds to that obtained at a flow rate of 25-29 ml/min in a counterflow elutriation method using a rotor equivalent to Beckman JE 5.0 spun at 900.times.g. This population of cells consists essentially of very early progenitor cells and the cells are useful in autologous bone marrow transplantation as well as gene therapy.Type: GrantFiled: June 6, 1995Date of Patent: September 15, 1998Assignees: Regents of University of Minnesota, Rhone-Poulenc Rorer PharmaceuticalsInventors: John E. Wagner, Jane S. Lebkowski
-
Patent number: 5780280Abstract: Simplified methods to produce recombinant adeno-associated virus (rAAV) vectors are described. The methods involve the use of chimeric plasmids which incorporate the Epstein Barr nuclear antigen (EBNA) gene, the latent origin of replication of Epstein Barr virus (oriP), and a rAAV genome. The chimeric plasmids themselves are also a part of the present invention. These plasmids are maintained as multicopy extra-chromosomal elements in cells, such as human 293 cells. Permanent cell lines carrying these EBV/AAV plasmids are induced to produce large amounts of rAAV upon addition of wild-type, adeno-associated virus helper functions. Vectors produced in this manner are capable of transducing exogenous genes into other human cell lines and exhibit the attributes of viral elements produced by conventional methods.Type: GrantFiled: June 2, 1995Date of Patent: July 14, 1998Assignee: Rhone-Poulenc Rorer Pharmaceuticals, Inc.Inventors: Jane S. Lebkowski, Maureen A. McNally, Thomas B. Okarma
-
Patent number: 5691176Abstract: Simplified methods to produce recombinant adeno-associated virus (rAAV) vectors are described. The methods involve the use of chimeric plasmids which incorporate the Epstein Barr nuclear antigen (EBNA) gene, the latent origin of replication of Epstein Barr virus (oriP), and a rAAV genome. The chimeric plasmids themselves are also a part of the present invention. These plasmids are maintained as multicopy extra-chromosomal elements in cells, such as human 293 cells. Permanent cell lines carrying these EBV/AAV plasmids are induced to produce large amounts of rAAV upon addition of wild-type, adeno-associated virus helper functions. Vectors produced in this manner are capable of transducing exogenous genes into other human cell lines and exhibit the attributes of viral elements produced by conventional methods.Type: GrantFiled: June 2, 1995Date of Patent: November 25, 1997Assignee: Applied Immune Sciences, Inc.Inventors: Jane S. Lebkowski, Maureen A. McNally, Thomas B. Okarma
-
Patent number: 5681731Abstract: Simplified methods to produce recombinant adeno-associated virus (rAAV) vectors are described. The methods involve the use of chimeric plasmids which incorporate the Epstein Barr nuclear antigen (EBNA) gene, the latent origin of replication of Epstein Barr virus (oriP), and a rAAV genome. The chimeric plasmids themselves are also a part of the present invention. These plasmids are maintained as multicopy extra-chromosomal elements in cells, such as human 293 cells. Permanent cell lines carrying these EBV/AAV plasmids are induced to produce large amounts of rAAV upon addition of wild-type, adeno-associated virus helper functions. Vectors produced in this manner are capable of transducing exogenous genes into other human cell lines and exhibit the attributes of viral elements produced by conventional methods.Type: GrantFiled: June 2, 1995Date of Patent: October 28, 1997Assignee: Applied Immune Sciences, Inc.Inventors: Jane S. Lebkowski, Maureen A. McNally, Thomas B. Okarma
-
Patent number: 5589377Abstract: Simplified methods to produce recombinant adeno-associated virus (rAAV) vectors are described. The AAV rep and cap genes are combined in a single recombinant adenovirus vector, i.e., a rep/cap adenovirus vector which combines in a single vector all complementing functions required for rAAV production. The rep/cap vectors of the present invention comprise: genes encoding helper functions, preferably from adenovirus, sufficient to permit AAV replication; and AAV cap and rep genes. In adenovirus rep/cap vectors the rep and cap genes may, for example, replace the adenovirus E3 gene or the adenovirus E1a and E1b genes.Type: GrantFiled: June 6, 1995Date of Patent: December 31, 1996Assignee: Rhone-Poulenc Rorer Pharmaceuticals, Inc.Inventors: Jane S. Lebkowski, Maureen A. McNally, Thomas B. Okarma
-
Patent number: 5354678Abstract: Simplified methods to produce recombinant adeno-associated virus (rAAV) vectors are described. The methods involve the use of chimeric plasmids which incorporate the Epstein Barr nuclear antigen (EBNA) gene, the latent origin of replication of Epstein Barr virus (oriP), and a rAAV genome. The chimeric plasmids themselves are also a part of the present invention. These plasmids are maintained as multicopy extra-chromosomal elements in cells, such as human 293 cells. Permanent cell lines carrying these EBV/AAV plasmids are induced to produce large amounts of rAAV upon addition of wild-type, adeno-associated virus helper functions. Vectors produced in this manner are capable of transducing exogenous genes into other human cell lines and exhibit the attributes of vital elements produced by conventional methods.Type: GrantFiled: December 21, 1992Date of Patent: October 11, 1994Assignee: Applied Immune Sciences, Inc.Inventors: Jane S. Lebkowski, Maureen A. McNally, Thomas B. Okarma
-
Patent number: 5173414Abstract: A simplified method to produce recombinant adeno-associated virus (AAV) vectors is described. The procedure involves the use of chimeric plasmids which incorporate the Epstein Barr nuclear antigen (EBNA) gene, the latent origin of replication of Epstein Barr Virus (oriP), and a recombinant AAV genome. The chimeric plasmids themselves are also a part of the present invention. These EBV/AAV plasmids are maintained as multicopy extra-chromosomal elements in cells, such as human 293 cells. Permanent cell lines carrying these EBV/AAV plasmids are induced to produce large amounts of recombinant AAV virus upon addition of wild-type, adeno-associated virus helper functions. Recombinant AAV vectors produced in this manner are capable of transducing exogenous genes into other human cell lines and exhibit all of the attributes of viral elements produced by conventional methods.Type: GrantFiled: October 30, 1990Date of Patent: December 22, 1992Assignee: Applied Immune Sciences, Inc.Inventors: Jane S. Lebkowski, Maureen A. McNally, Thomas B. Okarma